Navigation Links
OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Date:2/15/2008

improve treatment outcomes in second-line prostate cancer," said Dr. Fred Saad, who is also the primary investigator in the study. "The data also suggests that retreatment with docetaxel when combined with OGX-011 may reverse chemotherapy resistance in second-line docetaxel retreatment. We look forward to confirming these data in planned Phase 3 studies."

About OGX-011

OGX-011 is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer indications and in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma. Increased clusterin production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration. Clusterin levels may be further increased in response to standard cancer therapies, including hormone ablation therapy, chemotherapy and radiation therapy. Clusterin expression is linked to disease progression, treatment resistance, poor prognosis and survival in scientific publications. For example, increased expression of clusterin in prostate cancer is closely correlated with increasing Gleason score, which is a strong prognostic factor for poor survival of patients with prostate cancer.

About OncoGenex

OncoGenex is a private biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company's three product candidates are designed to inhibit the production of specific proteins associated with treatment resistance and which are over-produced in response to a variety of cancer treatments. OGX-011 is completing evaluation in five Phase 2 clinical studies in prostate, lung, and breast cancers. O
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Understanding the ... channel-expressing cell lines, and the gap that currently exists ... that expand its industry-leading portfolio of validated ion channel ... ion channel-expressing cell lines, as ion channels control many ... control this activity creates the potential to treat a ...
(Date:7/10/2014)... July 10, 2014 Robert Harman, DVM, Founder ... company, is proud to announce the relaunch of his highly ... a new series called “ What are Stem Cells ?” ... honest and straightforward foundation in the basics of stem cell ... on the right type of treatment when considering regenerative medicine. ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
(Date:7/10/2014)... 10, 2014  Kainos Capital, a firm specializing in ... that it has acquired the Slim-Fast brand from Unilever. ... Terms of the transaction were not disclosed. ... business that markets ready-to-drink shakes, powders, bars and snacks ... and in the United Kingdom ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Kainos Capital Acquires Slim-Fast From Unilever 2
... genetics,(Nasdaq: DCGN ) today expressed its enthusiastic ... bill that, many years in the,making, is now ... be signed,promptly by President Bush. GINA would provide ... prohibiting discrimination against,individuals in matters of employment or ...
... April 25 Beckman,Coulter, Inc. (NYSE: BEC ... a quarterly dividend payout of seventeen cents ($0.17) ... 23, 2008 to all stockholders of,record on May ... payout of dividends., (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ), ...
... BERLIN, April 25 Processes and products based ... the chemical industry in a wide range of ... the field of industrial,biotechnology in Germany will be ... Bioprocessing (April 27-30, 2008) in Chicago, Illinois.,The panel ...
Cached Biology Technology:deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information 2deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information 3deCODE Lauds Federal Legislation to Ban Discrimination on the Basis of Genetic Information 4World Congress on Industrial Biotechnology: Germany Home to Top Biotech Research and Investment 2
(Date:7/10/2014)... stabilize or even improve the state of fisheries ... in the Mediterranean has deteriorated over the past ... fish species reported in the Cell Press journal ... call for stringent monitoring of Mediterranean fishing activities, ... plans in Mediterranean waters. , Their data show ...
(Date:7/10/2014)... Poor peepers are a problem, even if you are ... an imperious predator, scouring the shallow waters for any ... eye exam by Yale University scientists, you,re reduced to ... night. , Such is the lot of the giant ... new paper by Yale paleontologists, published in the journal ...
(Date:7/10/2014)... controversy centres around a family of enzymes known as ... group in their active site. At the centre of ... becomes oxidised (ferryl) when a reacting heme is in ... has remained unanswered for decades is whether this oxidation ... group (OH). Resolving this fundamental question has implications for ...
Breaking Biology News(10 mins):Mediterranean fish stocks show steady decline 2Extinct sea scorpion gets a Yale eye exam, with surprising results 2Neutron crystallography solves long-standing biological mystery 2Neutron crystallography solves long-standing biological mystery 3
... record of oxygen concentration in the earth's atmosphere shows that ... gave mammals the evolutionary boost they needed to dominate the ... and lead author of a paper published Sept. 30 ... have measured the abundance of carbon 13, a byproduct ...
... have learned how to selectively shut down a flyweight-sized ... that may help doctors better understand cancer, birth defects ... be reported this week in the online Proceedings of ... of genetic material called microRNAs. , Once thought to ...
... A team of researchers from the Department of Biochemistry ... the Universitat Autònoma de Barcelona has discovered that tetanus ... a therapy against psychological disorders such as depression, anxiety ... disorders such as Parkinson's disease. , Tetanus toxin is ...
Cached Biology News:Oxygen increase caused mammals to triumph, researchers say 2Micro-molecule plays big role in birth defects 2Tetanus toxin found to have therapeutic properties 2
...
...
...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Biology Products: